Business Wire

VA-REGULA

29.2.2024 08:01:32 CET | Business Wire | Press release

Share
Regula Hits Remarkable 100 Million Online User Milestone Globally

Regula's expansion has been notably significant in three key markets: the United States, the United Arab Emirates, and Great Britain, which collectively account for over 35% of its global user base. The growth rates in these regions have been particularly impressive: United States – 216%; United Arab Emirates – 321%; United Kingdom – 95%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228514546/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Growth Trends: Regula User Expansion & Verification Scenarios in Key Markets (Graphic: Business Wire)

Not only do these figures highlight Regula's increasing prominence in these markets, but also underscore the global trust in the company’s technologies for secure and reliable identity verification. What sets Regula apart is its independence from third-party solutions, with all technologies developed internally. Regula offers a single-vendor solution for identity verification, combining biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with advanced authenticity validation, as well as forensic tools for detailed analysis.

The rise of full authenticity checks

The results of the survey conducted by Regula at the beginning of 2023 highlight an increase in identity fraud. The most prevalent form of fraudulent activity experienced by organizations was the use of fake or modified physical documents. 26% of small and medium businesses (SMBs) and 38% of enterprises experienced more than 50 identity fraud incidents during the previous year. The cost was also significant, with 64% of all businesses reporting losses of at least $120,000, and 37% of the world’s largest businesses reporting losses of at least $480,000.

In response to the evolving landscape of digital fraud, Regula has intensively focused on enhancing its techniques aimed at validating document authenticity. Its advanced authentication method facilitates verification of ID security features, as well as document liveness validation. This processing scenario has seen astounding growth rates in the United States (367%), United Arab Emirates (400%), and United Kingdom (86%).

Strengthening security with cross-validation

Regula also reports a steady increase in the adoption of its cross-validation checks, which provide maximum confidence in the consistency and authenticity of identity document data. These checks help ensure data integrity by cross-comparing personal details or biometric information provided on an identification document.

Growth rates in this area are equally remarkable: United States – 156%, United Arab Emirates – 257%, United Kingdom – 244%.

Regula's extensive proprietary database, which includes more than 13,600 document templates from 249 countries and territories and supports over 138 languages, is central to the success of these checks.

Diverse user engagement across platforms

A key advantage of Regula's identity verification solutions is their compatibility across various platforms, allowing for seamless ID verification processes, whether on mobile, web, desktop, or passport reading devices.

The company's success is demonstrated through its provision of hardware and software solutions for digital identity verification, serving a worldwide network of more than 1,000 organizations and 80 border control authorities. Some of the world's most innovative and reputable organizations rely on Regula’s hardware and software solutions to solve a range of challenges. For example:

  • UBS, the largest private bank in the world, has applied a robust customer onboarding system thanks to Regula’s comprehensive identity verification solutions.
  • FREENOW, a Mobility Super App, employs a set of Regula solutions to enable proper taxi driver identity verification to secure its ride-hailing services.
  • WizzAir and AirAsia use Regula solutions to expedite flight onboarding.
  • The Portuguese Immigration and Border Service has facilitated travel document verification by developing a mobile app based on Regula Document Reader SDK.
  • Pearson VUE, a global online testing giant, identifies users with the help of Regula technologies to grant admission to remotely administered professional exams.

"In this fiercely competitive market, it is imperative for all vendors to maintain a razor-sharp focus on delivering unwavering value to their users, ensuring that their services become indispensable components of daily operations," remarked Henry Patishman, Executive VP of Identity Verification Solutions at Regula. "Leveraging our deep-rooted expertise in both hardware and software, coupled with our strong and enduring connections within the forensic community, Regula has crafted a unique proposition. This combination of cutting-edge technology and forensic expertise allows us to deliver a deeply enriching experience for a wide range of applications to streamline onboarding and prevent identity fraud. Consequently, we have witnessed robust user adoption, a testament to our strategic investment in creating solutions that not only meet but exceed the expectations of our users in today’s dynamic environment."

For more information about Regula and its services, please visit Regula's website.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228514546/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye